
|Videos|December 27, 2022
Scynexis CEO talks recent ibrexafungerp approval
Author(s)Morgan Ebert, Managing Editor
Marco Taglietti, MD, president and CEO of Scynexis, sits with Contemporary OB/GYN® to discuss the recent approval of ibrexafungerp (Brexafemme) for the reduction in incidence of recurrent vulvovaginal candidiasis.
Advertisement
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA grants IDE approval for FemBloc non-surgical permanent birth control
2
Preterm HDP cases linked to greater CVD death in larger infants
3
Boosting cervical cancer screening in FQHCs could reach 1.8 million more women
4
Adverse pregnancy outcomes tied to long-term risk of atrial fibrillation
5
















